Special Session

Presidential Symposium II - EL08 - RT is Redefining the Cure of Metastatic Breast Cancer

9/15/2019
10:15 AM - 11:45 AM
Location: Room W185

Session Type: Special Session
0.00 AMA PRA Category 1 Credits™

Radiation therapy plays a major role in the management of breast cancer and its application in the aggressive management of metastatic disease continues to increase. Currently there are ongoing controversies as well as trials addressing the management of oligometastatic disease in patients presenting with a new diagnosis of breast cancer, patients presenting with a history of breast cancer who develop olgiometastasis, as well as management of the primary tumor in patients presenting with metastatic disease.
In this session we will have two speakers who will focus on the broad landscape of oligometastatic breast cancer and management issues and available data and gaps in the radiotherapeutic management of oligometastasis.

Following the featured lectures, there will be session breakouts followed by discussion and debate where participants will be allocated to one of 3 focus groups:
The role of radiation in first line therapy in patients with a history of breast cancer who present with oligometastatic disease.
The role of radiation and management of the primary in patients who present with a newly diagnosed breast cancer and oligometastatic disease.
The role of radiation and management of patients with metastatic breast cancer who present with oligo-progression of disease.
Following the session the participant should have a better understanding of the role of radiation, appropriate management, ongoing controversies and available or developing clinical trials in the management of oligometastic breast cancer.

Presentations:

Mylin Torres, MD

Emory University

Biography:


Dr. Mylin Torres is an Associate Professor in the Emory University School of Medicine Department of Radiation Oncology. She specializes in the treatment of breast cancer and is currently the Director of the Emory Glenn Family Breast Center and Louisa and Rand Glenn Family Chair in Breast Cancer Research. Her research program is dedicated to understanding the biology underlying treatment-related side effects, including chronic inflammation and cancer-related fatigue.

Dr. Torres has received highly competitive grants from the National Cancer Institute, Radiation Therapy Oncology Group, Susan G. Komen, Avon Foundation, NCCN, Pfizer Oncology, and Winship Cancer Institute to support her research and efforts to improve disparities among African American patients. She serves on the editorial board of the Journal of Clinical Oncology.
Dr. Torres holds the Louisa and Rand Glenn Family Chair in Breast Cancer Research at Winship Cancer Institute.

She received Atlanta Business Chronicle’s Healthcare Heroes Rising Star and Winship Cancer Institute’s Above and Beyond Awards. Atlanta Magazine also named her as one of the “Women Making a Mark” in the Atlanta community.

Dr. Torres graduated magna cum laude from Harvard University and received her medical degree from Stanford University before completing her training in radiation oncology at The University of Texas MD Anderson Cancer Center.

Presentation(s):

Send Email for Mylin Torres

Bruce Haffty, MD, FASTRO

Rutgers Cancer Institute of New Jersey

Biography:
Bruce G. Haffty, M.D., FACR, FASTRO, is Chief of Staff, Rutgers Cancer Institute of New Jersey, Professor and Chairman of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, New Jersey Medical School and Cancer Institute of New Jersey. His medical school, internship and residency training was at Yale. He spent the majority of his academic career at Yale, where he was Professor of Therapeutic Radiology, residency program director from 1992 through 2004, Vice Chairman and Clinical Director from 2002-2005. He moved to Rutgers Cancer Institute of New Jersey in 2005.
Dr. Haffty has a long and successful record in clinical and translational research in radiation oncology. He has focused his efforts on molecular/genetic factors as they relate to radiation resistance and outcomes in patients undergoing radiation. Dr. Haffty is also a leader in national clinical trials. He has coauthored a number of national clinical trials papers in high impact journals. He is currently co-investigator on several national clinical trials through the NRG and Alliance cooperative groups. He has published over 400 peer-reviewed articles, 30 book chapters, and numerous editorials and letters. He is consistently listed as one of the country’s leading physicians and best doctors through national registries.
In addition to a busy clinical practice, Dr. Haffty has served on numerous national committees related to research and education in breast cancer and radiation oncology. He is a Past President of the American Radium Society, past Chairman of the Residency Review Committee in Radiation Oncology, past President of the American Board of Radiology, and past President and Past Chairman of the Board of ASTRO. He currently serves as Deputy Editor of the Journal of Clinical Oncology and on the RSNA Board of Directors as the Science Liaison.

Presentation(s):

Send Email for Bruce Haffty

Wendy Woodward, MD, PhD

MD Anderson Cancer Center

Presentation(s):

Send Email for Wendy Woodward


Assets

Presidential Symposium II - EL08 - RT is Redefining the Cure of Metastatic Breast Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Presidential Symposium II - EL08 - RT is Redefining the Cure of Metastatic Breast Cancer